References
Key articles
World Health Organization. WHO guidelines for the treatment of patients with cystic echinococcosis. Jun 2025 [internet publication].Full text
White AC Jr, Coyle CM, Rajshekhar V, et al. Diagnosis and treatment of neurocysticercosis: 2017 clinical practice guidelines by the Infectious Diseases Society of America (IDSA) and the American Society of Tropical Medicine and Hygiene (ASTMH). Clin Infect Dis. 2018 Apr 3;66(8):e49-75.Full text Abstract
World Health Organization. WHO guidelines on management of Taenia solium neurocysticercosis. Sep 2021 [internet publication].Full text
Del Brutto OH, Nash TE, White AC Jr, et al. Revised diagnostic criteria for neurocysticercosis. J Neurol Sci. 2017 Jan 15;372:202-10.Full text Abstract
Reference articles
1. Schantz PM, Kern P, Brunetti R. Echinococcus. In: Guerrant RL, Walker DH, Weller PF, eds. Tropical infectious diseases: principles, pathogens and practice. 1st ed. Oxford, UK: Churchill Livingstone; 2005:1304-26.
2. Wittner M, Tanowitz HB, White AC. Taenia and other tapeworms. In: Guerrant RL, Walker DH, Weller PF, eds. Tropical infectious diseases: principles, pathogens and practice. 1st ed. Oxford, UK: Churchill Livingstone; 2005:1327-40.
3. Centers for Disease Control and Prevention. Human tapeworm (taeniasis): clinical overview of taeniasis. May 2024 [internet publication].Full text
4. Hernández-Orts JS, Scholz T, Brabec J, et al. High morphological plasticity and global geographical distribution of the Pacific broad tapeworm Adenocephalus pacificus (syn. Diphyllobothrium pacificum): molecular and morphological survey. Acta Trop. 2015 Sep;149:168-78. Abstract
5. Garcia HH, del Brutto OH. Taenia solium cysticercosis. Inf Dis Clin North Am. 2000 Mar;14(1):97-119. Abstract
6. Verastegui M, Gilman RH, Garcia HH, et al. Prevalence of antibodies to unique Taenia solium onchosphere antigens in Taeniasis and human and porcine cysticercosis. Am J Trop Med Hyg. 2003 Oct;69(4):438-44.Full text Abstract
7. Gonzalez AE, Garcia HH, Gilman RH, et al. Control of Taenia solium. Acta Trop. 2003 Jun;87(1):103-9. Abstract
8. Zoli A, Shey-Njila O, Assana E, et al. Regional status, epidemiology and impact of Taenia solium cysticercosis in Western and Central Africa. Acta Trop. 2003 Jun;87(1):35-42. Abstract
9. Centers for Disease Control and Prevention. Human tapeworm (taeniasis): about human tapeworm. Jun 2024 [internet publication].Full text
10. Braae UC, Thomas LF, Robertson LJ, et al. Epidemiology of Taenia saginata taeniosis/cysticercosis: a systematic review of the distribution in the Americas. Parasit Vectors. 2018 Sep 20;11(1):518.Full text Abstract
11. O'Neal SE, Flecker RH. Hospitalization frequency and charges for neurocysticercosis, United States, 2003-2012. Emerg Infect Dis. 2015 Jun;21(6):969-76.Full text Abstract
12. Balodhi A, Jain K, Gupta P, et al. A meta-analysis on the prevalence of Taenia solium and Taenia saginata infections in India. Trans R Soc Trop Med Hyg. 2023 Aug 3;117(8):539-45. Abstract
13. World Health Organization. Taeniasis/cysticercosis: fact sheet. Jan 2022 [internet publication].Full text
14. Laranjo-González M, Devleesschauwer B, Trevisan C, et al. Epidemiology of taeniosis/cysticercosis in Europe, a systematic review: Western Europe. Parasit Vectors. 2017 Jul 21;10(1):349.Full text Abstract
15. Scholz T, Garcia HH, Kuchta R, et al. Update on the human broad tapeworm (genus diphyllobothrium), including clinical relevance. Clin Microbiol Rev. 2009 Jan;22(1):146-60.Full text Abstract
16. Khalil HM, el Shimi S, Sarwat MA, et al. Recent study of Hymenolepis nana infection in Egyptian children. J Egypt Soc Parasitol. 1991 Apr;21(1):293-300. Abstract
17. Aria HP. Biology of the tapeworm Hymenolepis diminuta. New York, NY: Academic Press; 1980.
18. Biswas H, Arora RR, Sehgal S. Epidemiology of Hymenolepis nana infections in a selected rural community. J Commun Dis. 1978;10(3):170-4.
19. Mason PR, Patterson BA. Epidemiology of Hymenolepis nana infections in primary school children in urban and rural communities in Zimbabwe. J Parasitol. 1994 Apr;80(2):245-50. Abstract
20. World Health Organization. WHO guidelines for the treatment of patients with cystic echinococcosis. Jun 2025 [internet publication].Full text
21. World Health Organization. Echinococcosis: fact sheet. May 2021 [internet publication].Full text
22. Karshima SN, Ahmed MI, Adamu NB, et al. Africa-wide meta-analysis on the prevalence and distribution of human cystic echinococcosis and canine Echinococcus granulosus infections. Parasit Vectors. 2022 Oct 5;15(1):357.Full text Abstract
23. Kakamad FH, Anwar KA, Ahmed HK, et al. Risk factors associated with human echinococcosis: a systematic review and meta-analysis. Front Vet Sci. 2024;11:1480579.Full text Abstract
24. Centers for Disease Control and Prevention. Cysticercosis: clinical overview of cysticercosis. Mar 2024 [internet publication].Full text
25. Del Brutto OH, Sotelo J, Roman GC. Neurocysticercosis: a clinical handbook. Lisse, The Netherlands: Swets and Zeitlinger; 1998.
26. Bandres JC, White AC Jr, Samo T, et al. Extraparenchymal neurocysticercosis: report of five cases and review of management. Clin Infect Dis. 1992 Nov;15(5):799-811. Abstract
27. Garcia HH, Wittner M, Coyle CM, et al. Cysticercosis. In: Guerrant RL, Walker DH, Weller PF, eds. Tropical infectious diseases: principles, pathogens and practice. 1st ed. Oxford, UK: Churchill Livingstone; 2005:1289-303.
28. Elmonir W, Elaadli H, Amer A, et al. Prevalence of intestinal parasitic infections and their associated risk factors among preschool and school children in Egypt. PLoS One. 2021;16(9):e0258037.Full text Abstract
29. Gelaw A, Anagaw B, Nigussie B, et al. Prevalence of intestinal parasitic infections and risk factors among schoolchildren at the University of Gondar Community School, Northwest Ethiopia: a cross-sectional study. BMC Public Health. 2013 Apr 5;13:304.Full text Abstract
30. Openshaw JJ, Medina A, Felt SA, et al. Prevalence and risk factors for Taenia solium cysticercosis in school-aged children: a school based study in western Sichuan, People's Republic of China. PLoS Negl Trop Dis. 2018 May;12(5):e0006465.Full text Abstract
31. Pan American Health Organization. Guideline for preventive chemotherapy for the control of Taenia solium taeniasis. Sep 2021 [internet publication].Full text
32. Garcia HH, Gonzalez AE, Tsang VC, et al. Elimination of Taenia solium transmission in northern Peru. N Engl J Med. 2016 Jun 16;374(24):2335-44.Full text Abstract
33. World Health Organization. Early detection and management of neurological serious adverse events in relation to the administration of anthelminthic medicines to people with asymptomatic neurocysticercosis. Sep 2023 [internet publication].Full text
34. Di Lernia V, Ricci C, Albertini G. Skin eruption associated with Hymenolepis nana infection. Int J Dermatol. 2004 May;43(5):357-9. Abstract
35. Muehlenbachs A, Bhatnagar J, Agudelo CA, et al. Malignant transformation of Hymenolepis nana in a human host. N Engl J Med. 2015 Nov 5;373(19):1845-52.Full text Abstract
36. Conn DB. Malignant transformation of Hymenolepis nana in a human host. N Engl J Med. 2016 Mar 31;374(13):1293-4. Abstract
37. Saeedan MB, Aljohani IM, Alghofaily KA, et al. Thoracic hydatid disease: a radiologic review of unusual cases. World J Clin Cases. 2020 Apr 6;8(7):1203-12.Full text Abstract
38. Bumann S, Kuenzli E, Lissandrin R, et al. Cardiac cystic echinococcosis-a systematic review and analysis of the literature. PLoS Negl Trop Dis. 2024 May;18(5):e0012183.Full text Abstract
39. Aledavoud A, Mohammadi M, Ataei A, et al. Thyroid involvement in cystic echinococcosis: a systematic review. BMC Infect Dis. 2024 Aug 29;24(1):889.Full text Abstract
40. Rascio L, Donati T, Pascucci D, et al. Rare presentation of echinococcal disease: a systematic review on arterial hydatid cyst. Ann Vasc Surg. 2025 Mar;112:22-31. Abstract
41. Cuetter AC, Garcia-Bobadilla J, Guerra LG, et al. Neurocysticercosis: focus on intraventricular disease. Clin Infect Dis. 1997 Feb;24(2):157-64. Abstract
42. Department of Health, Victoria State Government, Australia. Taeniasis (tapeworm). Oct 2015 [internet publication].Full text
43. White AC Jr, Coyle CM, Rajshekhar V, et al. Diagnosis and treatment of neurocysticercosis: 2017 clinical practice guidelines by the Infectious Diseases Society of America (IDSA) and the American Society of Tropical Medicine and Hygiene (ASTMH). Clin Infect Dis. 2018 Apr 3;66(8):e49-75.Full text Abstract
44. Centers for Disease Control and Prevention. Cysticercosis: Clinical testing guidance for cysticercosis. Jun 2024 [internet publication].Full text
45. Proaño-Navarez JV, Meza-Lucas A, Mata-Ruiz O, et al. Laboratory diagnosis of human neurocysticercosis: double-blind comparison of enzyme-linked immunosorbent assay and electroimmunotransfer blot assay. J Clin Microbiol Rev. 2002 Jun;40(6):2115-8.Full text Abstract
46. World Health Organization. WHO guidelines on management of Taenia solium neurocysticercosis. Sep 2021 [internet publication].Full text
47. Webb CM, White AC Jr. Update on the diagnosis and management of neurocysticercosis. Curr Infect Dis Rep. 2016 Dec;18(12):44. Abstract
48. Mejia R, Nutman TB. Evaluation and differential diagnosis of marked, persistent eosinophilia. Semin Hematol. 2012 Apr;49(2):149-59.Full text Abstract
49. Groove D. A history of human helminthology. Wallingford, UK: CAB International; 1990.
50. Garcia HH, Gilman R, Martinez M, et al. Cysticercosis as a major cause of epilepsy in Peru. Lancet. 1993 Jan 23;341(8839):197-200. Abstract
51. Del Brutto OH, Nash TE, White AC Jr, et al. Revised diagnostic criteria for neurocysticercosis. J Neurol Sci. 2017 Jan 15;372:202-10.Full text Abstract
52. Carpio A, Fleury A, Romo ML, et al. New diagnostic criteria for neurocysticercosis: reliability and validity. Ann Neurol. 2016 Sep;80(3):434-42.Full text Abstract
53. World Health Organization. Expert consensus for the diagnosis and treatment of cystic and alveolar echinococcosis in humans. Nov 2009 [internet publication].Full text
54. White AC Jr, Garcia HH. Updates on the management of neurocysticercosis. Curr Opin Infect Dis. 2018 Oct;31(5):377-82. Abstract
55. Centers for Disease Control and Prevention. Human tapeworm (taeniasis): clinical treatment of taeniasis. May 2024 [internet publication].Full text
56. Centers for Disease Control and Prevention. Cysticercosis: clinical care of cysticercosis. Mar 2024 [internet publication].Full text
57. Proaňo JV, Madrazo I, Avelar F, et al. Medical treatment for neurocysticercosis characterized by giant subarachnoid cysts. N Engl J Med. 2001 Sep 20;345(12):879-85.Full text Abstract
58. Mitre E, Talaat KR, Sperling MR, et al. Methotrexate as a corticosteroid-sparing agent in complicated neurocysticercosis. Clin Infect Dis. 2007 Feb 15;44(4):549-53. Abstract
59. Garg RK, Rizvi I, Nigam H, et al. Treatment outcome in patients with spinal neurocysticercosis: a systematic review of published cases and case series. Future Microbiol. 2025 Jan;20(1):45-56.Full text Abstract
60. Garcia HH, Lescano AG, Gonzales I, et al. Cysticidal efficacy of combined treatment with praziquantel and albendazole for parenchymal brain cysticercosis. Clin Infect Dis. 2016 Jun 1;62(11):1375-9. Abstract
61. Garcia HH, Gonzales I, Lescano AG, et al. Efficacy of combined antiparasitic therapy with praziquantel and albendazole for neurocysticercosis: a double-blind, randomised controlled trial. Lancet Infect Dis. 2014 Aug;14(8):687-95. Abstract
62. Dewi DAR, Irawati Tjahjo Widuri L, Allatib A, et al. Effectiveness of the antiparasitic combination of albendazole and praziquantel as compared with albendazole monotherapy in the treatment of neurocysticercosis in children: a systematic review and meta-analysis. Cureus. 2024 Jul;16(7):e64617.Full text Abstract
63. Monk E, Abba K, Ranganathan L. Anthelmintics for people with neurocysticercosis. Cochrane Database Syst Rev. 2021 Jun 1;6(6):CD000215.Full text Abstract
64. Walton D, Castell H, Collie C, et al. Antiepileptic drugs for seizure control in people with neurocysticercosis. Cochrane Database Syst Rev. 2021 Nov 1;11(11):CD009027.Full text Abstract
65. Garcia HH, Gonzales I, Lescano AG, et al. Enhanced steroid dosing reduces seizures during antiparasitic treatment for cysticercosis and early after. Epilepsia. 2014 Sep;55(9):1452-9.Full text Abstract
66. Khuroo MS, Wani NA, Javid G, et al. Percutaneous drainage compared with surgery for hepatic hydatid cysts. N Engl J Med. 1997 Sep 25;337(13):881-7.Full text Abstract
67. Smego RA Jr, Bhatti S, Khaliq AA, et al. Percutaneous aspiration-injection-reaspiration drainage plus albendazole or mebendazole for hepatic cystic echinococcosis: a meta-analysis. Clin Infect Dis. 2003 Oct 15;37(8):1073-83. Abstract
68. Kuehn R, Uchiumi LJ, Tamarozzi F. Treatment of uncomplicated hepatic cystic echinococcosis (hydatid disease). Cochrane Database Syst Rev. 2024 Jul 12;7(7):CD015573.Full text Abstract
69. An G, Murry DJ, Gajurel K, et al. Pharmacokinetics, safety, and tolerability of oxfendazole in healthy volunteers: a randomized, placebo-controlled first-in-human single-dose escalation study. Antimicrob Agents Chemother. 2019 Apr;63(4):e02255-18.Full text Abstract
70. Bach T, Galbiati S, Kennedy JK, et al. Pharmacokinetics, safety, and tolerability of oxfendazole in healthy adults in an open-label phase 1 multiple ascending dose and food effect study. Antimicrob Agents Chemother. 2020 Oct 20;64(11):e01018-20.Full text Abstract
71. ClinicalTrials.gov. Oxfendazole in mild parenchymal brain cysticercosis. ClinicalTrials.gov Identifier: NCT06565507. Nov 2024 [internet publication].Full text
72. Alzoubi M, Daradkeh S, Daradka K, et al. The recurrence rate after primary resection cystic echinococcosis: a meta-analysis and systematic literature review. Asian J Surg. 2024 Sep 28:S1015-9584(24)02081-5.Full text Abstract
73. The Medical Letter. Drugs for parasitic infections. New Rochelle, NY: The Medical Letter; 2007.
Use of this content is subject to our disclaimer